Antiviral Efficacy of Pralatrexate against SARS-CoV-2

被引：9

作者：

Bae, Joon-Yong ^{[1
]}

Lee, Gee Eun ^{[1
]}

Park, Heedo ^{[1
]}

Cho, Juyoung ^{[1
]}

Kim, Jeonghun ^{[1
]}

Lee, Jungmin ^{[1
]}

Kim, Kisoon ^{[1
]}

Kim, Jin Il ^{[1
,2
]}

Park, Man-Seong ^{[1
,2
]}

机构：

[1] Korea Univ, Inst Viral Dis, Dept Microbiol, Coll Med, Seoul 02841, South Korea

[2] Korea Univ, Biosafety Ctr, Coll Med, Seoul 02841, South Korea

来源：

BIOMOLECULES & THERAPEUTICS | 2021年 / 29卷 / 03期

基金：

新加坡国家研究基金会;

关键词：

Antiviral; COVID-19; Drug repurposing; SARS-CoV-2;

D O I：

10.4062/biomolther.2021.032

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Novel coronavirus (SARS-CoV-2) has caused more than 100 million confirmed cases of human infectious disease (COVID-19) since December 2019 to paralyze our global community. However, only limited access has been allowed to COVID-19 vaccines and antiviral treatment options. Here, we report the efficacy of the anticancer drug pralatrexate against SARS-CoV-2. In Vero and human lung epithelial Calu-3 cells, pralatrexate reduced viral RNA copies of SARS-CoV-2 without detectable cytotoxicity, and viral replication was successfully inhibited in a dose-dependent manner. In a time-to-addition assay, pralatrexate treatment at almost half a day after infection also exhibited inhibitory effects on the replication of SARS-CoV-2 in Calu-3 cells. Taken together, these results suggest the potential of pralatrexate as a drug repurposing COVID-19 remedy.

引用

页码：268 / 272

页数：5

共 19 条

[1]

[Anonymous], 2020, LANCET, V396, P71, DOI 10.1016/S0140-6736(20)31517-8

[2]

Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI [10.1056/NEJMoa2007764, 10.1056/NEJMc2022236]

[3]

CDC, 2021, COVID data tracker in United States Centers for Disease Control and Prevention

[4]

Centers for Disease Control and Prevention, 2021, COVID data tracker

[5]

Centers for Disease Control and Prevention (CDC), 2021, DIFF COVID 19 VACC

[6] Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR (Publication with Expression of Concern) [J].

Corman, Victor M. ;

Landt, Olfert ;

Kaiser, Marco ;

Molenkamp, Richard ;

Meijer, Adam ;

Chu, Daniel K. W. ;

Bleicker, Tobias ;

Bruenink, Sebastian ;

Schneider, Julia ;

Schmidt, Marie Luisa ;

Mulders, Daphne G. J. C. ;

Haagmans, Bart L. ;

van der Veer, Bas ;

van den Brink, Sharon ;

Wijsman, Lisa ;

Goderski, Gabriel ;

Romette, Jean-Louis ;

Ellis, Joanna ;

Zambon, Maria ;

Peiris, Malik ;

Goossens, Herman ;

Reusken, Chantal ;

Koopmans, Marion P. G. ;

Drosten, Christian .

EUROSURVEILLANCE, 2020, 25 (03) :23-30

[7]

Drugbank, 2021, PRAL ACC NUMB DB0681

[8]

ECDC, 2021, COVID 19 SIT UPD EU

[9]

FDA, 2020, COVID 19 TREATM GUID

[10] Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis [J].

Hong, Jung Yong ;

Yoon, Dok Hyun ;

Yoon, Sang Eun ;

Kim, Seok Jin ;

Lee, Ho Sup ;

Eom, Hyeon-Seok ;

Lee, Hye Won ;

Shin, Dong-Yeop ;

Koh, Youngil ;

Yoon, Sung-Soo ;

Jo, Jae-Cheol ;

Kim, Jin Seok ;

Kim, Soo-Jeong ;

Cho, Su-Hee ;

Lee, Won-Sik ;

Won, Jong-Ho ;

Kim, Won Seog ;

Suh, Cheolwon .

SCIENTIFIC REPORTS, 2019, 9 (1)

← 1 2 →